LRP1 and early-onset autosomal dominant Alzheimer disease: Thus, the regulation of LRP1 in the liver is a promising target for Alzheimer’s disease therapy, and LRP1 activators, such as plant extracts, anti-diabetic drugs, and statins, may form the basis for further development of new therapeutic approaches.